Blood Cancer Research Assays

Deep molecular profiling of blood cancers

Archer Blood Cancer research assays leverage a powerful technology for error-corrected next-generation sequencing for high sensitivity oncogene profiling.


Archer® Blood Cancer research assays detect various driver mutations in hematologic malignancies, such as myeloid and lymphoid diseases, by targeted next-generation sequencing (NGS).

This approach combines FusionPlex® and VariantPlex® panels to characterize gene fusions, point mutations, copy number variations (CNVs) and other variant types from a single sample.

Key Features


All Archer panels are powered by Anchored Multiplex PCR (AMP™) chemistry and thus follow the same workflow for maximum lab efficiency.

Comprehensive Tumor Profiling

Get the most information from your sample - fusions, CNVs, SNVs, indels and expression levels.

Error Correction & Quantit ative Analysis

Molecular barcode sequences ligated prior to amplification enable duplicate read binning and advanced error correction for confident variant calls.

Sensitive & Specific Variant Detection

Powerful bioinformatics combined with orthogonal variant verification.

Our Blood Cancer Research Assays

Archer® FusionPlex RUO panels generate target-enriched libraries from RNA to characterize gene fusions, splice variants, SNVs, indels and relative expression levels by next-generation sequencing (NGS) on Illumina® and Ion Torrent™ platforms.


Archer® VariantPlex RUO panels combine patented enrichment chemistry, an easy workflow and powerful bioinformatics to generate target-enriched libraries from DNA to confidently detect copy number variations (CNVs), single-nucleotide variants (SNVs) and indels by next-generation sequencing (NGS).

Recent publications utilizing these assay
Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples.
Detection of Novel t(12;17)(p12;p13) in Relapsed Refractory Acute Myeloid Leukemia by Anchored Multiplex PCR(AMP)-based Next-Generation Sequencing.
menu home-icon-silhouette remove-button twitter linkedin-1 facebook-circular-logo right